Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration

Nutlin-3a is an MDM2 inhibitor that is under investigation in preclinical models for a variety of pediatric malignancies, including retinoblastoma, rhabdomyosarcoma, neuroblastoma, and leukemia. We used physiologically based pharmacokinetic (PBPK) modeling to characterize the disposition of nutlin-3a in the mouse. Plasma protein binding and blood partitioning were assessed by in vitro studies. After intravenous (10 and 20 mg/kg) and oral (50, 100, and 200 mg/kg) dosing, tissue concentrations of nutlin-3a were determined in plasma, liver, spleen, intestine, muscle, lung, adipose, bone marrow, adrenal gland, brain, retina, and vitreous fluid. The PBPK model was simultaneously fit to all pharmacokinetic data using NONMEM. Nutlin-3a exhibited nonlinear binding to murine plasma proteins, with the unbound fraction ranging from 0.7 to 11.8%. Nutlin-3a disposition was characterized by rapid absorption with peak plasma concentrations at approximately 2 h and biphasic elimination consistent with a saturable clearance process. The final PBPK model successfully described the plasma and tissue disposition of nutlin-3a. Simulations suggested high bioavailability, rapid attainment of steady state, and little accumulation when administered once or twice daily at dosages up to 400 mg/kg. The final model was used to perform simulations of unbound tissue concentrations to determine which dosing regimens are appropriate for preclinical models of several pediatric malignancies.

[1]  J. Lunec,et al.  The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.

[2]  K. Pang,et al.  Nonlinear protein binding and enzyme heterogeneity: Effects on hepatic drug removal , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  宮地 充.  Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells , 2010 .

[4]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[5]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Interaction for Cancer Therapy , 2008, Clinical Cancer Research.

[6]  L. Mayo,et al.  Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. , 2007, Cancer research.

[7]  J. Lunec,et al.  Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. , 2001, Cancer research.

[8]  Hong Wan,et al.  High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry. , 2006, Journal of chromatography. A.

[9]  C. Stewart,et al.  Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). , 2010, Journal of pharmaceutical and biomedical analysis.

[10]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[11]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[12]  J. Pulido,et al.  Protein levels in the vitreous of rats with streptozotocin-induced diabetes mellitus , 1993, Brain Research Bulletin.

[13]  L. Vassilev.  p53 Activation by small molecules: application in oncology. , 2005, Journal of medicinal chemistry.

[14]  William S Wright,et al.  Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist. , 2009, Experimental eye research.

[15]  T. Amemiya,et al.  Vitreous seeds in retinoblastoma, clinical significance and ultrastructure , 1979, Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie.

[16]  F. Speleman,et al.  Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. , 2009, Journal of the National Cancer Institute.

[17]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[18]  Hsiao-Huei Wu,et al.  MDM2--master regulator of the p53 tumor suppressor protein. , 2000, Gene.

[19]  D. Cobrinik,et al.  Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. , 2006, Archives of ophthalmology.

[20]  C. Pratt,et al.  St. Jude Children's Research Hospital. , 1997, Pediatric hematology and oncology.

[21]  C. Shields.  Forget-Me-Nots in the Care of Children with Retinoblastoma , 2008, Seminars in ophthalmology.

[22]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[23]  L. Huang,et al.  Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. , 2009, Carcinogenesis.

[24]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[25]  F. Violante,et al.  Simultaneous determination of low levels of methotrexate and cyclophosphamide in human urine by micro liquid chromatography/electrospray ionization tandem mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[26]  L. Vassilev,et al.  Targeting the p53–MDM2 interaction to treat cancer , 2004, British Journal of Cancer.

[27]  S. Berg,et al.  MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death , 2006, Molecular Cancer Therapeutics.

[28]  P. Ojala,et al.  p53 Reactivation Kills KSHV Lymphomas Efficiently In Vitro and In Vivo: New Hope for Treating Aggressive Viral Lymphomas , 2007, Cell cycle.

[29]  A. Rowan.  Guide for the Care and Use of Laboratory Animals , 1979 .

[30]  M. Relling,et al.  Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma , 2005, Clinical Cancer Research.

[31]  Jindrich Cinatl,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. , 2009, Cancer research.

[32]  R. Bristow,et al.  Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53 , 2008, Molecular Cancer Therapeutics.

[33]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[34]  A. Albini,et al.  Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3 , 2007, Circulation research.

[35]  I. Kariv,et al.  Development of a high throughput equilibrium dialysis method. , 2001, Journal of pharmaceutical sciences.

[36]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[37]  Jun Wang,et al.  Small-Molecule Inhibition of TNF-α , 2005, Science.